stella
Ulcerative ColitisOctober 2024Summary reviewed November 2026

Subcutaneous Infliximab Doubled Remission Rates in Moderate-to-Severe Ulcerative Colitis

In a large Phase 3 trial, patients with moderate-to-severe ulcerative colitis who responded to IV infliximab induction were randomized to receive either subcutaneous infliximab or placebo every 2 weeks for maintenance. By week 54, those on the injection achieved remission at nearly double the rate of placebo recipients.

What the trial was testing

The LIBERTY-UC enrolled 548 patients with ulcerative colitis. The study was sponsored by Celltrion and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

43% of patients on subcutaneous infliximab achieved remission versus 21% on placebo.

Gastroenterology · 2024 · NCT04205643

These findings — that subcutaneous infliximab achieved remission in 43% of patients versus 21% on placebo — were published in the Gastroenterology and represent the headline result of the study.

Researchers tracked outcomes across 548 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with ulcerative colitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This treatment more than doubled the chance of remission in people with moderate-to-severe ulcerative colitis who had already improved with IV infliximab. The subcutaneous form is given as an injection at home every 2 weeks and was well tolerated with no new safety concerns. Talk to your doctor about whether this maintenance option fits your situation.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open ulcerative colitis trials

RecruitingObservational study

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

Houston, Texas, United States
RecruitingSafety & dosing / Early efficacy

Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor. Primary non-response to risankizumab is high in both CD and UC. Currently, there are no predictors of response to risankizumab and the actual mechanism of action has not yet been elucidated. To gain better understanding of the drug targeting of risankizumab in IBD, the University Medical Center Groningen (UMCG) developed fluorescently labeled risankizumab (risankizumab-800CW). This study aims to assess the safety and the optimal dose of risankizumab-800CW to visualize and potentially quantify the local drug concentration and predict treatment response in IBD patients using in vivo and ex vivo fluorescence molecular imaging (FMI).

Groningen, Netherlands